This study will evaluate the safety and effectiveness of a new intravenous (IV) medication (LT3001) for adult patients who have had a stroke. This new medication is designed to restore blood flow to the area of the brain affected, and reduce inflammation in the brain. Patients who agree to be in this study will receive 6 doses of the IV study drug while in the hospital. Patients will have extra labs drawn, head imaging studies and will be followed by the study team for 90 days after their hospital admission.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
James Ho
Neurology
Clinical or Medical
Interventional
Brain, Head, Nervous System
23-0140
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
